As Artificial Intelligence becomes more popular in everyday life, drug research and development companies are incorporating ...

The objective of the Preclinical Development Program (PDEV) is to accelerate completion of preclinical development, FDA IND clearance, and clinical trial startup for stem cell-based and genetic ...

Charles River Laboratories, a leading provider of preclinical drug development services, has reported impressive results in ...

Makers of organoids and cell models cheered the decision and said it will bolster the development of precision medicines, ...

Inductive Bio, a technology company democratizing artificial intelligence (AI) models to transform small molecule drug discovery, announced today that it has raised $25M in Series A financing led by ...

The transition from preclinical development to clinical trials is a critical, with approximately 89% of drugs failing. Nearly half of these failures stem from unexpected and unmanageable human ...

AI business Recursion Pharmaceuticals has narrowed its drug development ... Recursion is pausing development of REC-4539, a clinical-stage oncology candidate. A preclinical programme in an ...

Columbia University, the Company’s collaboration partner for pre-clinical development, granted Silo an exclusive global license to further develop, manufacture, and commercialize SPC-15 worldwide.